Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity
Allergy · 2025
DOI: 10.1111/all.16323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Hilal Demir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Aus…. Hauptthemen laut MEDLINE: Allergens, Antigens, Plant, Plant Proteins, Desensitization, Immunologic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Austrian Science Fund, Danube Allergy Research Cluster.
Abstract (Originalsprache)
Background
In contrast to sublingual immunotherapy (SLIT) with recombinant Mal d 1 (rMal d 1‐SLIT), SLIT with rBet v 1 (rBet v 1‐SLIT) induced Mal d 1‐cross‐reactive antibodies without IgE‐blocking activity. To elucidate whether the development of cross‐protective IgG responses depends on the degree of molecular identity of allergens we compared the cross‐reactivity, cross‐blocking activity, and affinity of SLIT‐induced antibodies with allergens of varying amino acid sequence identities to Bet v 1 and Mal d 1, namely Cor a 1.04 (hazelnut), Pru av 1 (cherry), and Dau c 1 (carrot).
Methods
Allergen‐specific antibodies were quantified by ELISA. IgE blocking was analyzed by inhibition of allergen‐induced basophil activation and IgE‐facilitated allergen‐presentation to T cells. The affinity of SLIT‐induced antibodies was studied by acidic dissociation ELISA and competition ELISA. Identical surface areas on allergens were predicted using an in‐house designed script based on structural alignments. Results rBet v 1‐SLIT‐induced IgG antibodies cross‐reacted with all allergens except Dau c 1. rMal d 1‐SLIT‐induced antibodies predominantly cross‐reacted with Pru av 1 and displayed significantly higher IgE blocking to Pru av 1 than rBet v 1‐SLIT‐induced antibodies. rMal d 1‐SLIT‐induced IgG1 showed higher affinity to Mal d 1 and Pru av 1. Surface analysis revealed 84% identical area on Mal d 1 and Pru av 1. Furthermore, we identified two surface areas potentially containing epitopes present on these allergens and absent on Bet v 1.
Conclusion
In summary, our findings suggest that a relatively high threshold of similarity is required to establish effective cross‐blocking antibodies to related allergens. Apparently, the structural identity between Bet v 1 and Mal d 1 is below this threshold. Therefore, this study may explain why immunotherapy with birch pollen allergen often fails to reduce birch pollen‐related apple allergy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
- Molecular Allergology, Paul-Ehrlich-Institute, Langen, Germany.
- Department of Dermatology, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Christian Radauer, Barbara Bohle
Förderung
- Austrian Science Fund
- Danube Allergy Research Cluster
Zitieren
APA
Demir, H., Radauer, C., Strobl, M. R., Scheurer, S., Kinaciyan, T., & Bohle, B. (2025). Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity. Allergy. https://doi.org/10.1111/all.16323
Vancouver
Demir H, Radauer C, Strobl MR, Scheurer S, Kinaciyan T, Bohle B. Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity. Allergy. 2025. doi:10.1111/all.16323
BibTeX
@article{Demir2025,
author = {Demir, Hilal and Radauer, Christian and Strobl, Maria R and Scheurer, Stephan and Kinaciyan, Tamar and Bohle, Barbara},
title = {Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16323}
}
EUVIMED